Pharmacokinetic and pharmacogenetic evaluation of triapine

• In: Miscellaneous - Posters
• At: Beijing (China) (2007)
• Type: Poster
• Poster code: M-P-035
• By: KOLESAR, Jill (University of Wisconsin, Madison, United States of America)
• Co-author(s): Pomplun, Marcia (University of Wisconsin, MADISON, United States of America)
  Steinmetz, Matt (University of Wisconsin, MADISON, United States of America)
  Hahn, Kris (University of Wisconsin, MADISON, United States of America)
  Holen, Kyle (University of Wisconsin, MADISON, United States of America)
  Traynor, Anne (University of Wisconsin, MADISON, United States of America)
  Stewart, James (University of Wisconsin, MADISON, United States of America)
  Alberti, Dona (University of Wisconsin, MADISON, United States of America)
  Eickhoff, Jens (University of Wisconsin, MADISON, United States of America)
  Wilding, George (University of Wisconsin, MADISON, United States of America)
  
• Abstract:

  Aims: Triapine is a ribunucleotide reductase inhibitor being developed for the treatment of cancer and is a substrate for the efflux pump, p-glycoprotein (pGp). Functional polymorphisms in the ABCB1 gene coding for pGp are frequent and patients (pts) with variant genotypes may have altered Triapine pharmacokinetics (pks), efficacy and toxicity. ..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login